A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations
Open Access
- 12 May 2022
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (17) , 3639-3651
Abstract
Radiotherapy has proven efficacy in a wide range of cancers. There is growing interest in evaluating radiotherapy–novel agent combinations and a drive to initiate this earlier in the clinical development of the novel agent, where the scientific rationale and preclinical evidence for a radiotherapy combination approach are high. Optimal design, delivery, and interpretation of studies are essential. In particular, the design of phase I studies to determine safety and dosing is critical to an efficient development strategy. There is significant interest in early-phase research among scientific and clinical communities over recent years, at a time when the scrutiny of the trial methodology has significantly increased. To enhance trial design, optimize safety, and promote efficient trial conduct, this position paper reviews the current phase I trial design landscape. Key design characteristics extracted from 37 methodology papers were used to define a road map and a design selection process for phase I radiotherapy–novel agent trials. Design selection is based on single- or dual-therapy dose escalation, dose-limiting toxicity categorization, maximum tolerated dose determination, subgroup evaluation, software availability, and design performance. Fifteen of the 37 designs were identified as being immediately accessible and relevant to radiotherapy–novel agent phase I trials. Applied examples of using the road map are presented. Developing these studies is intensive, highlighting the need for funding and statistical input early in the trial development to ensure appropriate design and implementation from the outset. The application of this road map will improve the design of phase I radiotherapy–novel agent combination trials, enabling a more efficient development pathway.Keywords
Funding Information
- NIHR (BRC-1215–20014)
- Cancer Research UK (C7852/A25447, C19942/A28832)
This publication has 72 references indexed in Scilit:
- Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical TrialsJournal of Biopharmaceutical Statistics, 2013
- Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted AgentsPLOS ONE, 2012
- Using the time‐to‐event continual reassessment method in the presence of partial ordersStatistics in Medicine, 2012
- Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersBritish Journal of Cancer, 2011
- Dose‐finding approach for dose escalation with overdose control considering incomplete observationsStatistics in Medicine, 2011
- A systematic methodology review of phase I radiation dose escalation trialsRadiotherapy and Oncology, 2010
- Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time-to-Event OutcomesJournal of the Royal Statistical Society Series C: Applied Statistics, 2009
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI: Journal of the National Cancer Institute, 2009
- Monitoring late-onset toxicities in phase I trials using predicted risksBiostatistics, 2007
- New concepts for phase I trials: evaluating new drugs combined with radiation therapyNature Clinical Practice Oncology, 2005